Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists

Tamara Pérez-Jeldres1,2,3, Christopher J. Tyler1,4, Joshua D. Boyer1,4, Thangaraj Karuppuchamy1,4, Andrés Yarur3, Daniel A. Giles3, Shaila Yeasmin1, Luke Lundborg1, William J. Sandborn1, Derek R. Patel1 and Jesús Rivera-Nieves1,4

1 Inflammatory Bowel Disease Center, Division of Gastroenterology, University of California, San Diego, La Jolla, CA, United States, 2 Department of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile, 3 San Borja Arriarán Clinic Hospital, Santiago, Chile, 4 VA San Diego Healthcare System, San Diego, CA, United States, 5 Division of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, WI, United States, 6 La Jolla Institute for Allergy and Immunology, San Diego, CA, United States

The inflammatory Bowel diseases (IBDs) are a chronic, relapsing inflammatory diseases of the gastrointestinal tract with heterogeneous behavior and prognosis. The introduction of biological therapies including anti-TNF, anti-IL-12/23, and anti-integrins, has revolutionized the treatment of IBD, but these drugs are not universally effective. Due to the complex molecular structures of biologics, they are uniformly immunogenic. New discoveries concerning the underlying mechanisms involved in the pathogenesis of IBD have allowed for progress in the development of new treatment options. The advantage of small molecules (SMs) over biological therapies includes their lack of immunogenicity, short half-life, oral administration, and low manufacturing cost. Among these, the Janus Kinases (JAKs) inhibition has emerged as a novel strategy to modulate downstream cytokine signaling during immune-mediated diseases. These drugs target various cytokine signaling pathways that participate in the pathogenesis of IBD. Tofacitinib, a JAK inhibitor targeting predominantly JAK1 and JAK3, has been approved for the treatment of ulcerative colitis (UC), and there are other specific JAK inhibitors under development that may be effective in Crohn’s. Similarly, the traffic of lymphocytes can now be targeted by another SM. Sphingosine-1-phosphate receptor (S1PR) agonism is a novel strategy that acts, in part, by interfering with lymphocyte recirculation, through blockade of lymphocyte egress from lymph nodes. S1PR agonists are being studied in IBD and other immune-mediated disorders. This review will focus on SM drugs approved and under development, including JAK inhibitors (tofacitinib, filgotinib, upadacitinib, peficitinib) and S1PR agonists (KRP-203, fingolimod, ozanimod, etrasimod, amiselimod), and their mechanism of action.

Keywords: IBD, small molecules, JAK inhibitors, S1P agonists, MOA
INTRODUCTION

Inflammatory Bowel diseases (IBDs) is a chronic immune-mediated condition of the gastrointestinal tract (Abraham and Cho, 2009). It is potentially caused by a dysregulated mucosal immune response to intestinal microflora in genetically predisposed hosts (Abraham and Cho, 2009). There are currently no curative therapies, and in most cases, lifelong treatment is required (Abraham and Cho, 2009). Non-specific immunomodulatory drugs such as glucocorticoids, sulfasalazine/5-aminosalicylates, methotrexate, and thiopurines were among the first drugs used to treat IBD (Soendergaard et al., 2018). The introduction of biologics during the last 20 years has revolutionized the treatment of IBD, and several anti-TNF monoclonal antibodies (mAbs) (including infliximab, adalimumab, certolizumab pegol, and golimumab) are commonly used. More recently, antibodies with a different mechanism of action (MOA), such as anti-integrin α4β7 (vedolizumab) and anti-IL12/IL23 (ustekinumab), became available for clinical use (Olivera et al., 2016). However, mAbs have limitations in terms of safety, cost, and sustained efficacy (Hemperly et al., 2018). In fact, around 10–30% of patients treated with anti-TNF are primary non-responders to therapy, and 23–46% are secondary non-responders (Hemperly et al., 2018). For these reasons, novel orally available drugs are still in great need and are being developed to treat IBD. The present review will focus on new families of chemically synthesized SM drugs already available or under development: Janus Kinases (JAK) inhibitors and sphingosine-1-phosphate receptor (S1PR) agonists, with emphasis on their MOA.

Differences Between Small Molecules and Monoclonal Antibodies

Monoclonal antibodies are large molecules with high molecular weights (~150 kDa) (Samanen, 2013). The mAb structure consists of four polypeptide chains, two identical heavy chains, and two identical light chains. Each mAb molecule has an antigen-binding region (Fab) or variable region, and a constant region or Fc (Ordás et al., 2012). The size and structure of the mAb determines the drug pharmacokinetic, target location, the drug–drug interaction, the antigenicity, and the route of administration. The mAbs are eliminated from the circulation by catabolism, which depends on the rates of proteolysis (extracellular degradation), recycling rates [by interaction with Brambell or the neonatal Fc receptor (FcRn)], and receptor-mediated antibody endocytosis rates (Ordás et al., 2012). Due to the large size of mAb the renal clearance is insignificant (Hemperly et al., 2018). Because of the protein composition of mAbs, the immune system can recognize them as immunogenic foreign antigens, which may lead to the development of specific anti-drug antibodies that nullify their therapeutic effect (Ordás et al., 2012; Yarur and Rubin, 2015; Hemperly et al., 2018). This results in increased drug clearance and ultimately may contribute to treatment failure and/or hypersensitivity reactions (Ordás et al., 2012; Yarur and Rubin, 2015; Hemperly et al., 2018). The addition of immunomodulators can decrease anti-drug antibody formation but increases the risks associated with immunosupression (Ordás et al., 2012; Yarur and Rubin, 2015; Hemperly et al., 2018).

The term SM typically refers to organic compounds with low molecular weights, usually <1 kDa, which enables them to diffuse easily through cell membranes to reach intracellular targets (Samanen, 2013; Murphy and Zheng, 2015). Many SM inhibitors can function as immunomodulators due to their ability to specifically block intracellular signaling pathways thought to be pivotal to the pathogenesis of IBD (Samanen, 2013; Murphy and Zheng, 2015; Olivera et al., 2016). SMs have several advantages over conventional immunotherapeutic agents, including ease of administration (oral, without infusion costs), stable structures, non-immunogenic, potentially short half-lives, and usually lower manufacturing costs (Samanen, 2013; Murphy and Zheng, 2015; Olivera et al., 2016). Table 1 compares the main differences between SM and mAb (Samanen, 2013).

### JAK-STAT Pathway and JAK Inhibitors

Cytokines are released by the immune system in response to a stimulus (Abbas et al., 2014b). They bind to specific receptors, triggering activation and initiation of intracellular signaling pathways (Abbas et al., 2014b). Cytokines encompass many structurally unrelated proteins that are grouped based on their binding to distinct receptor super families, which

| Small molecules | Monoclonal antibodies |
|-----------------|-----------------------|
| Molecular weight | Low (<1000 Da)         | High (>1000 Da)         |
| Preparation     | Chemical synthesis    | Biologically produced   |
| Structure       | Small organic compounds| Proteins                |
| Route of administration | Oral               | Parenteral              |
| Location of target | Intracellular        | Extracellular           |
| Distribution    | Variable in organs/tissues/cells | Limited to plasma and/or extracellular fluids |
| Metabolism      | Metabolized typically by liver and gut CYPs into no active and active metabolites | Catabolism by proteolytic degradation to peptides and amino acids |
| Clearance       | The clearance can be by renal excretion, biliary excretion, hepatic metabolism, and intestinal transporters | Mainly involves the reticuloendothelial system (RES) through proteolytic catabolism |
| Toxicity        | Can produce specific toxicity due to parent or metabolites (often "off the target") | Receptor-mediated toxicity |
| Antigenicity-hypersensitivity | No antigenic, but can show unpredictable hypersensitivity | Potential |
| Drug-drug interaction | Pharmacokinetic interactions by competitive clearance mechanism as: –Decreasing clearance by enzyme inhibition –Increasing clearance by enzyme induction | Infrequent |

| Mechanism of action | Receiver or enzyme inhibition | Depletion |

---

**TABLE 1 | Comparison of properties of SM drugs and mAbs (Samanen, 2013).**
include Type I cytokine receptors, Type II cytokine receptors, the
TNF receptor family, the IL-1 receptor family, and G-protein-
coupled receptors. Each family of receptors utilizes different
mechanisms of signal transduction (Table 2; Abbas et al., 2014b).
The cytokines bind to the extracellular domain of the receptor,
and trigger intracellular changes, resulting in signal transduction
that drives changes in gene expression (Clark et al., 2013;
Abbas et al., 2014b). Protein kinases have an essential role in
the signal transduction pathway of these receptors, and are
an attractive target to regulate the inflammatory response (Clark
et al., 2013; Abbas et al., 2014b). However, due to the complexity
and redundancy inherent to signal transduction networks, some
of these kinases may be better therapeutic targets than others
(Clark et al., 2013).

The JAK family is a small family of receptor-associated
tyrosine kinases that are essential for the cytokine signaling
cascade, downstream of Type I and Type II cytokine receptors
(Schwartz et al., 2017). The JAK-signal transducers and activators
of transcription (STAT) pathway plays an important role in innate
immunity, adaptive immunity, and hematopoiesis, participating
in cellular processes such as cell growth, survival, differentiation,
and migration (Table 2; Banerjee et al., 2017; Olivera et al.,
2017). There are four members of the JAK family (JAK1, JAK2,
JAK3, and TYK2) and seven signal transducers and transcription
activators called signal transducer and activator of transcription,
or STAT (STAT 1–4, 5a, 5b, and 6) (Clark et al., 2013; Banerjee
et al., 2017; Olivera et al., 2017; Schwartz et al., 2017; Table 3).

The unique structure of each JAK clearly distinguishes them
from other members of the protein tyrosine kinase family
(Banerjee et al., 2017). The JAKs contain four functional
domains: the SH2 domain (a scaffold for STAT), the FERM
domain (regulates catalytic activity and mediates association
with receptors and other proteins), the pseudo-tyrosine kinase
domain, and a catalytically active tyrosine kinase domain
(Banerjee et al., 2017). These last two domains are the basis for the
name of the protein family named Janus (the two-faced Roman
god of beginnings, endings, and duality), thus JAK exhibits a
domain with kinase activity, while the other negatively regulates
the activity of the first (Banerjee et al., 2017).

Canonical JAK-STAT signaling starts with the binding
between cytokines and their corresponding transmembrane
receptors, allowing receptor dimerization and triggering the
transactivation of JAK, followed by phosphorylation of the
cyttoplasmic tails of the receptors that produce coupling sites
for STAT, resulting in the tyrosine-phosphorylation (p-Tyr) of the
STAT by JAK (Jatiani et al., 2010; Villarino et al., 2017).
After these events, STAT (like homo/heterodimers) translocate

### Table 2 | Cytokines, receptors, and transduction pathway.

| Ligands | Cytokine receptor | Transduction pathway | Function |
|---------|-------------------|----------------------|----------|
| Epo, Tpo, G-CSF, GH, and PRL | Homodimer receptor | JAK-STAT (JAK2) | Erythropoiesis Myelopoiesis |
| IL-3, IL-5, and GM-CSF | Common β chain | JAK-STAT (JAK2) | Myelopoiesis |
| IL-6, IL-11, IL-23, and OSM | gp-130 | JAK-STAT (mainly JAK1 but also JAK2, TYK2) | Myelopoiesis |
| IL-2, IL-4, IL-7, IL-9, IL-13, IL-15, and IL-21 | Common γ chain | JAK-STAT (JAK1, JAK3) | Myelopoiesis |
| IFNα, IFNβ, IFNγ, IFN-10, and IFN-22 | Type II | JAK-STAT (JAK1, JAK2, TYK2) | Antiviral |
| TNFα, TNFβ, LT, CD40, Fasl, RANTES, April, OX40, GTR, nerve growth factor | TNF receptor family | TRAF | Inflammation |
| IL-1, IL-18, IL-33 | IL-1 receptor family | IRAK | Inflammation |
| Chemokines | Seven transmembrane G-proteins coupled receptors | | |

**Epo**, erythropoietin; **Tpo**, thrombopoietin; **G-CSF**, granulocyte-colony stimulating factor; **GH**, growth hormone; **PRL**, prolactin; **IL**, interleukin; **GM-CSF**, granulocyte-macrophage colony-stimulating factor; **OSM**, oncostatin M; **TNF**, tumor necrosis factor; **LT**, lymphotoxin; **FasL**, Fas ligand; **BAFF**, B-cell activating factor; **GTR**, glucocorticoid-induced TNF receptor; **JAK**, Janus kinase; **STAT**, signal transducers and activators of transcription; **TRAF**, TNF receptor-associated factors; **IRAK**, interleukin-1 receptor-associated kinases (Abbas et al., 2014b).

### Table 3 | STAT and cellular function.

| STAT | Cellular function |
|------|-------------------|
| 1    | Cell growth and apoptosis TH1 cell-specific cytokine production Antimicrobial defense |
| 2    | Mediation of IFN-α/IFN-β signaling |
| 3    | Cell proliferation and survival Inflammation Immune response Embryonic development Cell motility |
| 4    | TH1 cell differentiation Inflammation responses Cell proliferation |
| 5A   | Cell proliferation and survival IL-2Ra expression in T lymphocytes Mammary gland development Lactogenic signaling |
| 5B   | Cell proliferation and survival IL-2Ra expression in T lymphocytes Sexual dimorphism of body growth rate NK cell cytolytic activity |
| 6    | Inflammatory and allergic immune response B-cell and T-cell proliferation TH2 cell differentiation |

**TH1**, T helper; **IFN**, interferon; **IL**, interleukin. Table adapted from Miklossy et al. (2013). Therapeutic modulators of STAT signaling for human diseases (Miklossy et al. 2014).
FIGURE 1 | Signaling by receptors Type I and Type II cytokines. (A) Type I and type II cytokine receptors comprise subunits that physically associate with Janus kinases (JAKs). Type I and type II cytokine depend on JAKs to transduce intracellular signals. JAK proteins share four components: the kinase domain, the pseudokinase domain, the FERM domain, and the SH2 domain. 1, the canonical JAK-STAT signaling begins with the extracellular association between cytokines and their corresponding transmembrane receptors. 2, the receptor dimerization triggers the transactivation of JAK. 3. Phosphorylation of the cytoplasmic tails of the receptors that create docking sites for STATs. 4–6, STAT binds to JAK, allowing the tyrosine phosphorylation of STAT which results in STAT dimerization, nuclear translocation, DNA binding, and ultimately, modulation of gene transcription. Unphosphorylated STAT dimers also have regulatory functions, although these functions are less well defined. (B) 1, monoclonal antibodies can block Type I and Type II cytokines and their receptors. 2, by contrast, JAK inhibitors block cytokine signaling, binding to the kinase domain of JAK in the ATP-binding site, avoiding their phosphorylation and JAK activation, preventing STAT phosphorylation and other substrates, so intracellular signals cannot be transduced (Schwartz et al., 2017).

to the nucleus, bind to DNA, and modulate gene transcription (Jatiani et al., 2010; Villarino et al., 2017). In addition to STAT phosphorylation, other kinases such as Src, phosphoinositide 3-kinases (PI3K), and RAF can be phosphorylated, activating additional signaling pathways involving proteins including Akt, and extracellular signal-regulated kinases (ERK) (Figure 1; Jatiani et al., 2010).

Signal transducers and activators of transcription is under the control of physiological negative regulators such as (i) suppressors of cytokine signaling (SOCS), that inhibit the kinase activity, binding phospho-tyrosine residues and competing with STAT at cytoplasmic level, (ii) protein tyrosine phosphatases (PTPs) that inactivate JAK and STAT in both the nucleus and the cytoplasm, (iii) protein inhibitor of activated STAT family (PIAS) that interferes at the nuclear level with STAT-mediated transcription and triggers proteasome degradation, and (iv) the modulators SH2B adaptor protein that increase or decrease JAK activation (Villarino et al., 2017).

Many cytokines implicated in the pathogenesis of immune-mediated diseases use the JAK-STAT pathway, representing a potential therapeutic target for these disorders (Jatiani et al., 2010; Clark et al., 2013; Banerjee et al., 2017; Olivera et al., 2017; Schwartz et al., 2017; Villarino et al., 2017). The mAbs can block Type I and Type II cytokines and their receptors. By contrast, JAK
inhibitors block cytokine signaling, binding to kinase domain of JAK at the ATP-binding site, avoiding their phosphorylation and JAK activation, preventing STAT phosphorylation and other substrates, so intracellular signals cannot be transduced (Jatiani et al., 2010; Clark et al., 2013; Banerjee et al., 2017; Olivera et al., 2017; Schwartz et al., 2017; Villarino et al., 2017). Other potential therapeutic candidates include STAT-binding inhibitory peptides, STAT-targeting small interfering RNA (siRNA), and STAT-binding decoy oligonucleotides (Schwartz et al., 2017; Villarino et al., 2017).

The JAK inhibitors have been used in the treatment of hematologic disorders (Jatiani et al., 2010). In recent years, these inhibitors have received attention for the treatment of autoimmune/immune-mediated disorders such as rheumatoid arthritis (RA) (Vanhoutte et al., 2017), systemic lupus erythematosus (SLE) (ClinicalTrials.gov, ClinicalTrials, 2018e), dermatomyositis (Hornung et al., 2014), Sjogren syndrome (ClinicalTrials.gov, ClinicalTrials, 2018n), vasculitis (Zhang et al., 2018), psoriasis (Hsu and Armstrong, 2014), alopecia areata (Divito and Kupper, 2014), atopic dermatitis (Levy et al., 2018), psoriasis (Hsu and Armstrong, 2014), alopecia areata (Divito and Kupper, 2014), atopic dermatitis (Levy et al., 2015), vitiligo (Liu et al., 2017), and IBD (Panés et al., 2017; Sandborn et al., 2017a; Vermeire et al., 2017a).

**JAK Inhibitors for the Treatment of IBD**

Typically, IBD is associated with chronic inflammation, defined by a dysregulated response of the innate and adaptive immune systems (Abraham and Cho, 2009; Boland and Vermeire, 2017). Chronic inflammation in Crohn’s disease (CD) is characterized by a response of helper T cells type 1 (Th1) and helper T cells type 17 (Th17), with inadequate activity of regulatory T cells (Treg), whereas UC has generally been considered a type 2 T helper cell cytokine profile (Th2) (Boland and Vermeire, 2017). In both diseases, many of the cytokines produced by these T cells signal through JAK receptors; therefore, JAK proteins have an important place in the signaling of inflammation in IBD (Boland and Vermeire, 2017).

Key cytokines in the pathogenesis of IBD belong to Type I (Th1 and Th17, and Type II cytokines receptors [i.e., IL-6, IL-5, IL-9, IL-10, IL-13, IL-12/23, IL-22, granulocyte–macrophage colony-stimulating factor (GM-CSF), IFN-γ] (Zhou et al., 2007; Dienz and Rincon, 2009; Abbas et al., 2014a,c; Flamant et al., 2017). These cytokines all signal through the JAK/STAT pathway. In contrast, the cytokines TNF, IL-1, and IL-17, which are the major drivers of IBD, do not use the JAK-STAT pathway in their signaling pathways (Zhou et al., 2007; Dienz and Rincon, 2009; Abbas et al., 2014a,c; Flamant et al., 2017). However, these cytokines induce the expression of a wide range of downstream pro-inflammatory cytokines, that in turn depend on JAK/STAT signaling (Zhou et al., 2007; Dienz and Rincon, 2009; Abbas et al., 2014a,c; Flamant et al., 2017).

Interleukin-6 (IL-6) along with oncostatin M (OSM) and IL-11 signal through the gp130-associated receptor family. IL-6 activates JAK1, JAK2, and TYK2 leading to STAT3 transduction, which promotes T cell proliferation, favoring the polarization of Th17 cells (Zhou et al., 2007; Banerjee et al., 2017). Notably, IL-6 can also promote Th2 differentiation (Dienz and Rincon, 2009). In addition, IL-6 has other functions relevant to IBD, such as regulating intestinal permeability, by its effects on tight junctions, regulating the proliferation of epithelium, and healing of wounds (Flamant et al., 2017).

Interleukin-12 and IL-23 also play an important role in IBD, and JAK2 and tyrosine kinases type 2 (TYK2) are involved in the signaling of these cytokines by activating STAT3 and STAT4, promoting inflammatory reactions through their ability to induce Th1 and Th17 polarization, respectively, and production of IFN-γ, IL-21, and IL-22 (Flamant et al., 2017).

Interleukin-10 is an anti-inflammatory cytokine produced by many immune cell populations, including activated macrophages, dendritic cells, regulatory T cells, Th1 and Th2 cells. IL-10 activates JAK1 and TYK2 proteins, leading to STAT3 phosphorylation (Abbas et al., 2014a). The anti-inflammatory effects of IL-10 results, in part, from its ability to inhibit the production of IL-12 by activated macrophages and dendritic cells as well as inhibiting the expression of costimulatory and class II MHC molecules in these cells (Abbas et al., 2014a).

Interleukin-22 is produced in epithelial tissues, especially in the skin and gastrointestinal tract. IL-22 activates JAK1 and TYK2, transducing signals via STAT3, STAT1, and STAT5. IL-22 has a role in maintaining epithelial integrity, mainly by promoting the barrier function of epithelial cells and by inducing production of anti-microbial peptides (Abbas et al., 2014c). However, IL-22 contributes to inflammation, in part by stimulating epithelial production of chemokines, and may therefore be involved in tissue injury in inflammatory diseases (Abbas et al., 2014c).

Interleukin-9 binding to its receptor leads to activation of JAK1 and JAK3, which in turn phosphorylates STAT1/STAT3 and STAT1/STAT5, respectively (Flamant et al., 2017). IL-9 has been associated with deleterious impact on intestinal epithelial wound healing (Flamant et al., 2017).

Interferon-γ activates JAK1 and JAK2, inducing STAT1 activation, resulting in macrophage activation, Th1 polarization, and increased expression of several proinflammatory cytokines. However, IFN-γ also has a protective function in epithelial healing (Flamant et al., 2017). Moreover, IFN-γ protects from tissue destruction by inhibiting the expression of genes that code for tissue destructive factors such as matrix metalloproteinases (MMPs), serine proteases, coagulation factors, complement components, and enzymes involved in the metabolism of prostaglandin. In addition, IFN-γ decreases neutrophil and monocytes infiltration (Hu and Ivashkin, 2009). GM-CSF activates Jak2 which phosphorylates STAT5, and STAT3 promoting monocye/macrophage/granulocyte survival and activation (Kimura et al., 2009; Flamant et al., 2017).

Drugs that block JAK/STAT signaling have the potential to alter multiple inflammatory pathways, being less specific in their action than drugs that target specific cytokines or their receptors (Soendergaard et al., 2018). This complexity is clear for IL-6 (pro-inflammatory) and IL-10 (anti-inflammatory) signaling, where both ligands, despite activating JAK1 and STAT3, have opposing functions (Soendergaard et al., 2018). Consequently, blocking JAK1 affects both IL-6 and IL-10, and may alter the inflammatory balance in both directions (Soendergaard et al., 2018). Additionally, JAK inhibitors can
result in undesirable adverse effects like cytopenia and infectious complications, through its blockade of GM-CSF and IFN-γ signaling, respectively (Clark et al., 2013). On the other hand, a major strength is their effectiveness. Through adequate plasma levels, these drugs induce partial and reversible inhibition of cytokine signaling, resulting in a better balance between the inflammatory and immunomodulatory response (Clark et al., 2013). More selective inhibition of the JAK-STAT pathway is being developed and may overcome the challenges of less selective inhibitors.

The US Food and Drug Administration (FDA), in May 2018, approved tofacitinib as the first JAK inhibitor to treat moderate severely active UC (Soendergaard et al., 2018). Similar to the FDA, the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) had a favorable opinion, and recommended their use in adult patients with moderately to severely active UC with inadequate or loss of response or intolerance to either conventional therapy or biological agents. Currently, no JAK inhibitors are approved for CD; however, other selective JAK inhibitors are in the pipeline for CD (Soendergaard et al., 2018).

**Tofacitinib**

Tofacitinib (Xeljanz, Pfizer) is a pan-JAK inhibitor, that preferentially inhibits JAK1 and JAK3, in a dose-dependent fashion (Sandborn et al., 2017a). Tofacitinib has a predicted gut availability of 93%, and the clearance is 70% hepatic, whereas the remaining 30% is cleared by renal metabolism (Hemperly et al., 2018). Tofacitinib's half-life is 3 h and neither age, gender, body weight, or disease severity at baseline have an effect on its clearance or plasma levels (Dowty et al., 2014).

A double-blind, placebo-controlled phase 2 study evaluated the efficacy of tofacitinib in patients with UC ($n = 194$) with moderate to severe activity (Sandborn et al., 2012). The patients were randomly assigned during 8 weeks to different tofacitinib doses (0.5, 3, 10, and 15 mg each 12 h) or placebo. The primary outcome at 8 weeks (clinical response established as the decrease of at least three points and at least 30% from the baseline total Mayo score, and decrease of at least one point or an absolute rectal bleeding sub-score of 0 or 1) reported a statistically significant response between the higher doses versus placebo (78% versus 42%, respectively) (Sandborn et al., 2012). These data were supported by phase 3, double-blind placebo-controlled studies; OCTAVE induction 1, 2, and OCTAVE sustain. In the induction trials; OCTAVE 1 ($n = 598$) and 2 ($n = 591$) trials, the patients were randomly assigned to receive 10 mg of tofacitinib twice daily or placebo during 8 weeks (Sandborn et al., 2017a). The primary endpoint was remission at week 8 (a total Mayo score of $\leq 2$, with no subscore $> 1$ and a rectal bleeding sub-score of 0). This endpoint was achieved in 18.5% in the tofacitinib-treated group versus 8.2% in the placebo group ($P = 0.007$); in the OCTAVE Induction 2 trial, remission was achieved in 16.6% versus 3.6% ($P < 0.001$). A total of 593 patients achieved clinical response after the induction therapy and were recruited in the OCTAVE Sustain trial to randomly receive tofacitinib as maintenance therapy (5 or 10 mg twice daily) or placebo during 52 weeks. The aim endpoint (remission at 52 week) was achieved in 34.3 and 40.6% (5 and 10 mg twice daily, respectively) versus 11.1% placebo ($P < 0.001$) (Sandborn et al., 2017a). Furthermore, mucosal healing was more frequent in the tofacitinib group, and tofacitinib was effective in both treated and naive to anti-TNF patients. The safety and efficacy data were evaluated in a phase 3, multicenter, open-label, long-term extension study in patients with severe to moderate UC ($n = 946$). Preliminary data showed that no new safety concerns emerged, compared with those observed in RA. Efficacy results from OLE study (NCT01470612) support sustained efficacy with tofacitinib at both 5 and 10 mg doses twice daily (Lichtenstein et al., 2017).

Similar studies were conducted in patients with moderate to severe CD; In a phase II ($n = 139$) study, patients were randomly assigned to receive tofacitinib (1, 5, or 15 mg twice daily) or placebo during 4 weeks. This study did not show a significant clinical response or remission response (Sandborn et al., 2014). Subsequently, another phase IIb study was performed. In this study, patients were randomized, during 8 induction weeks, to tofacitinib 5 mg twice per day ($n = 86$) or placebo ($n = 91$). The responders were included in the maintenance phase, during 26 weeks, to receive tofacitinib 5 or 10 mg daily or placebo. The majority of enrolled patients were previously treated with anti-TNF (76–79%). In this study, the results were also disappointing, despite the long duration of treatment, the remission rates did not reach significant differences (Panés et al., 2017).

These discouraging results in CD may be due to high placebo response rates or differences in the fundamental immunopathogenesis of CD and UC. Several factors may have contributed to the high placebo response observed, including lack of centralized reading endoscopy and absence of baseline objective markers of disease activity (Panés et al., 2017).

**Filgotinib** (GLPG0634, Galapagos/Gilead Sciences) is an oral JAK1 inhibitor, with enhanced selectivity for JAK1 over JAK2 and JAK3 (30 and 50 times, respectively) in blood (Vermeire et al., 2017a,b; Hemperly et al., 2018). Filgotinib dosing leads to the formation of active metabolite which exhibits a similar JAK1 selectivity profile as the parent compound, but has less potency (Vermeire et al., 2017a,b; Hemperly et al., 2018). Still, both contribute to the clinical activity of filgotinib. The half-life of filgotinib is 6 h, while the metabolite has a terminal elimination half-life of 21–27 h. Filgotinib and its metabolites are predominantly cleared renally (>80%) (Vermeire et al., 2017a,b; Hemperly et al., 2018).

FITZROY, a double-blind, placebo-controlled study, examined the efficacy and safety of filgotinib for the treatment of active moderate to severe CD (Vermeire et al., 2017a). A total of 174 patients with active CD were enrolled. Disease activity was confirmed by centrally read endoscopy. A proportion of patients achieved clinical remission with filgotinib 200 mg once a day, compared with placebo (47 versus 23%; $p = 0.077$) at week 10. Data also suggested that filgotinib is effective in anti-TNF exposed and naïve patients, being twofold higher in TNF-naïve group (Vermeire et al., 2017a). In addition, a recent post hoc analysis showed that clinical remission is still seen in CD, regardless of the disease location or duration (Vermeire et al., 2017b). Currently, there are phase III trials underway in both a CD and UC (ClinicalTrials.gov, ClinicalTrials, 2018h,i,j,m).
Peficitinib (GLPG1205, Janssen) is JAK1 and JAK3 inhibitor (Sands et al., 2018; Soendergaard et al., 2018). The efficacy and safety of the drug has been evaluated for the treatment of moderate to severe UC (n = 219) in a multicenter, randomized, double blind, placebo-controlled, phase IIb trial. Nevertheless, the development of this drug was discontinued in 2017 due to disappointing efficacy results (Sands et al., 2018; Soendergaard et al., 2018).

Upadacitinib (UPA) (ABT-494, Abbvie) is a JAK1-selective inhibitor. It is a non-sensitive substrate for cytochrome P450, approximately 20% is eliminated, unchanged, in urine (Hemperly et al., 2018). Its efficacy and safety were assessed in patients with moderate-to-severe CD who had inadequate response, or intolerance, to anti-TNF (Sandborn et al., 2017b). In this study, patients receiving 6 mg twice daily (27%) achieved clinical remission at a higher rate than placebo (11%). A significant dose–response relationship for endoscopic remission was observed in the UPA arm (Sandborn et al., 2017b). In addition, patients with moderate-to-severely active UC (n = 250), and history of inadequate response, loss of response or intolerance to corticosteroids, immunosuppressant, or biologic therapies, were included in a phase Ib double-blind placebo-controlled dose-ranging induction study, to assess the safety and efficacy of UPA. At week 8, both the primary objective: clinical remission per Adapted Mayo Score (stool frequency subscore ≤ 1, rectal bleeding score = 0, endoscopic score ≤ 1) and the secondary objectives: clinical remission per full Mayo score, clinical response per adapted Mayo score and endoscopic improvement were evaluated (Sandborn et al., 2018b). All of these objectives were achieved with different doses ranging from 15 to 45 mg QD. The tolerance to UPA was good and safety was similar to that of other UPA studies (Sandborn et al., 2018b). Phase III studies in CD and UC are ongoing (ClinicalTrials.gov, ClinicalTrials, 2018l,o,p).

TD-1473 (Theravance, Biopharma) is a new oral pan-JAK inhibitor being investigated (ClinicalTrials.gov, ClinicalTrials, 2018f; Soendergaard et al., 2018). Unlike other JAK inhibitors, its distribution is limited to the gastrointestinal tract, minimizing systemic toxicity and side effects (ClinicalTrials.gov, ClinicalTrials, 2018f; Soendergaard et al., 2018). Data from phase I study in healthy volunteers have shown that treatment with TD-1473 is safe and well-tolerated (Beattie et al., 2018). The safety, tolerability, and pharmacokinetics of TD-1473 were assessing in a double-blind placebo-controlled multicenter phase Ib study in subjects with moderately to severely active UC (n = 40) (ClinicalTrials.gov, ClinicalTrials, 2018f; Sandborn et al., 2018a). In this study, TD-1473 was generally well tolerated over 4 weeks with evidence of intestinal restriction, low systemic exposure, and signals for clinical and biomarker activity in subjects with moderately to severely active UC (ClinicalTrials.gov, ClinicalTrials, 2018f; Sandborn et al., 2018a).

Pf-06651600/Pfizer (JAK3 inhibitor) and Pf-06700841/Pfizer (TYK2/JAK1 inhibitor) are being tested in clinical trials to be completed by early 2020 (ClinicalTrials.gov, ClinicalTrials, 2018k,q).

Adverse Effects: Experience From IBD and Rheumatoid Arthritis

Most of the safety information currently for JAK inhibitors belongs to RA and psoriasis literature. For S1PR agonists most of the safety data originated from Multiple Sclerosis and IBD trials, as tofakinib and fingolimod were approved for those applications years earlier. Otherwise, post-marketing real-world data from clinical practice after the approval of tofakinib in immune-mediated disease as RA and IBD are available (Hsu and Armstrong, 2014; Charles-Schoeman et al., 2015; Liu et al., 2017; Schwartz et al., 2017; Winthrop, 2017; Cohen et al., 2018; Kang et al., 2018; Verden et al., 2018).

Tofakinib is the JAK inhibitor whose side effects are best known compared to other more specific JAK inhibitors. Still is unknown if the higher selectivity of the new JAK will result in fewer adverse effects (Winthrop, 2017).

Infections

The risk of serious infections during JAK inhibitor treatments is similar to that of biologics and most infections do not require treatment discontinuation. Nasopharyngitis and influenza are the most frequently reported infection-related adverse events. Tuberculosis and osteomyelitis are infrequent infections that also have been identified, and in this circumstance, the therapy must be interrupted (Winthrop, 2017). In addition, JAK inhibitors increase the risk of herpes zoster infection. However, Shingrix (recombinant zoster vaccine, GlaxoSmithKline) can reduce risk of infection and associated complications in patients treated with JAK inhibitors (Winthrop, 2017).

Other serious viral infections like nephropathy by BK virus (a polyoma virus) have been identified with the use of tofacitinib during renal transplantation (Schwartz et al., 2017). A few cases of cytomegalovirus (CMV) infections, including CMV retinitis, have occurred in patients under treatment with tofacitinib in the long-term extension studies (Sandborn et al., 2014; Schwartz et al., 2017; Winthrop, 2017). Also cases of abscesses, cellulitis, Clostridium difficile infection, pneumonia by Pneumocystis jiroveci, candida infections, urinary tract infections, and histoplasmosis have been reported (Sandborn et al., 2014).

Malignancy

All immunosuppressants have the potential to increase cancer risk. Accordingly, JAK inhibitors could interfere with T and NK immune vigilance against cancer and the antineoplastic role of IFN-γ (Schwartz et al., 2017).

Recently, the post marketing surveillance (PMS) data of worldwide tofacitinib use in RA, obtained from Pfizer safety database during a 3-year reporting period, was published. The estimated exposure to tofacitinib was 34,223 patient years. The overall relative risk was 0.45 per 100 patients-year, being highest during the first year and stabilizing later. The most notified neoplasms were lymphoma, skin, lung, breast, brain, prostate, uterine and colon cancer, malignant melanoma, squamous, and basal cell carcinoma. During the PMS, the most reported cancer in RA patients receiving tofacitinib therapy was the non-melanoma skin cancer (NMSC) (Cohen et al., 2018).
Dyslipidemia and Cardiovascular Events
A dose-dependent increase in HDL, LDL, and total cholesterol has been observed. Levels normalized after cessation of treatment. This change in lipid profiles has not been found to be associated with an increase of adverse cardiovascular events (Charles-Schoeman et al., 2015).

Thromboembolic events were reported during a placebo-controlled trial of baricitinib, a JAK inhibitor tested in RA. A post-marketing adverse event report from the FDA’s Adverse Event Reporting System did not show increased risk of thromboembolic events for tofacitinib, tofacitinib extended-release, or ruxolitinib. However, the data indicated that pulmonary thrombosis and portal vein thrombosis may be a class-wide risk for JAK inhibitors (Kang et al., 2018; Verden et al., 2018).

Anemia and Leukopenia
Because hematopoietic growth factors signal through JAK2, cytopenia is frequent with the use of the first-generation pan-JAK inhibitors. These alterations are usually well tolerated and do not require treatment discontinuation (Schwartz et al., 2017).

Pregnancy
There is a lack of information about the effect of JAK inhibitors during pregnancy since most studies exclude pregnant women, and there is little data available from patients who became pregnant while receiving the medication (Winthrop, 2017). The pregnancy results from patients with UC under tofacitinib exposure were reported. Mahadevan et al. (2018) notified that from 1157 UC patients recruited in intervention trials, 25 cases were reported (11 maternal, 14 paternal) with exposure to tofacitinib. These cases were reported 15 healthy neonates, 2 spontaneous abortions, and 2 medical interruptions. Cases of fetal death, neonate death, and congenital malformations were not described.

The data available to date does not allow to definitive position regarding the tofacitinib effect on pregnancy, and its use is not recommended (Mahadevan et al., 2018).

Others Adverse Events
Intestinal perforation and elevated serum liver enzymes have been reported with the use of tofacitinib (Olivera et al., 2016).

Future Perspectives
The pathogenesis of UC and CD involve different signaling pathways, which may explain the differential response to diverse drugs. The use of a drug with different MOA could be an effective alternative (i.e., tofacitinib for anti-TNF non-responders in UC). Further understanding the main pathways involved in the pathogenesis of IBD may predict the efficacy of specific drugs based on their MOA in the near future (Jabeen et al., 2015).

Janus kinases inhibitors target a broad spectrum of cytokines, and are a safe and effective treatment for immune-mediated disorders, such as IBD. As stated previously the JAK-STAT pathway plays an important role in innate and adaptive immunity, cell growth, survival, differentiation, and migration; hence, there are concerns of potential off-target effects. However, the safety profile to date is similar to other biological agents (Winthrop, 2017). Selectivity of the new JAK inhibitors may improve safety, while maintaining efficacy. The development of drugs such as TD-1473, with action limited to the gastrointestinal tract and less systemic exposure, may also improve safety.

In cases of refractory illness, an emergent idea is the combined use of drugs that target distinct pathways, such as inhibitors of kinase PI3K or receptor tyrosine kinases (RTKs) (Montor et al., 2018).

Signal transducers and activators of transcriptions do not have intrinsic catalytic activity unlike JAK and RTKs, whose kinase domains are an obvious therapeutic target. A potential and attractive approach is the inhibition of STAT using oligonucleotides, which would sequester STAT away from the nucleus. Small molecules (SMs), inhibitory peptides, and siRNAs that target STATs are also undergoing clinical trials for other diseases (Villarino et al., 2015; ClinicalTrials.gov, ClinicalTrials, 2018b).

The relative risk and benefits of these drugs as monotherapy, combination, or sequential therapy with other drugs remain incompletely characterized (Barroso et al., 2017).

S1P/S1PR Targeting
Sphingosine-1-phosphate (SIP) is a sphingosine-derived phospholipid that binds to 5 G-protein-coupled receptors (S1PR1-5) (Park and Im, 2017). The S1P receptors are involved in several physiological events and cellular processes, such as adhesion, migration, lymphocyte/hematopoietic cell trafficking, endocytosis, vascular tone and permeability, embryogenesis, angiogenesis, and cardiac function (Sanchez and Hla, 2004; Gonzalez-Cabrera et al., 2014).

Sphingolipids are important elements in the structure of cell membrane, and SIP is a sphingolipid metabolite derived from sphingosine. SIP is phosphorylated by sphingosine kinases 1 and 2, and reversibly dephosphorylated by sphingosine phosphatases 1,2, and by the action of SIP lyase, SIP is irreversibly degraded (Le Stunff et al., 2004; Figure 2).

Sphingosine-1-phosphate/S1PR1 interactions are relevant for lymphocyte trafficking through the thymus, secondary lymphoid organs, circulation, and tissues. SIP mediates the traffic of dendritic cells, B cells, and T cells (naive and central memory-CCR7-positive), but does not have a significant role in the chemotaxis of effector memory CCR7-negative T cells, which maintain tissue immune-surveillance (Abbas et al., 2014a; Perez-Jeldres et al., 2018). The SIP lyase distribution, higher in tissues but absent in the vasculature, favors an SIP concentration gradient between the blood (higher levels), lymph, secondary lymphoid organs, and tissues (lower levels), determining the movement from the areas with low concentration to high SIP concentration (Abbas et al., 2014a; Perez-Jeldres et al., 2018). Elevated SIP levels in blood induce S1PR1 internalization, whereas in the lymph node and tissues S1PR1 is re-expressed after some hours, and during this time the T cell is able to interact with antigen-presenting cells (Abbas et al., 2014a; Perez-Jeldres et al., 2018). Once S1PR1 re-appears on the surface of lymphocyte, these cells can leave the lymph node or tissue by...
sensing the higher S1P concentration in the blood, determining immune cell egress into the circulation (Horga and Montalban, 2008; Olivera et al., 2016).

Mechanisms of Action of S1PR Modulators

The native ligand S1P indices internalization of S1PR, which are recycled back to the cell surface within several hours, achieving a transitory lymphopenia (Park and Im, 2017). By contrast, S1PR1 agonists lead to the internalization of the receptor and subsequent ubiquitination and proteasome degradation of the receptor, producing sustained lymphopenia that renders lymphocytes incapable of following the S1P gradient and exiting the lymph node. This sequestration potentially prevents their access to sites of inflammation (Abbas et al., 2014a; Park and Im, 2017; Perez-Jeldres et al., 2018). In addition, S1PR1 is strongly expressed by lymphatic endothelium, where it tightens the lymphatic endothelial barrier. S1PR1 agonists can therefore interfere with lymphocyte trafficking by inhibiting transendothelial migration and blocking lymphocyte egress from the lymph node. These effects are reversed upon withdrawal of the agent (Horga and Montalban, 2008; Perez-Jeldres et al., 2018; Figure 3).

Sphingosine-1-phosphate signaling is involved in multiple immune functions. Therapies targeting the S1P axis may be applicable to treat autoimmune/immune-mediated diseases and have been tested in MS, RA, SLE, psoriasis, and IBD (Perez-Jeldres et al., 2018).

S1PR Modulators in IBD

Fingolimod/FTY720 (Gilenya™) is an S1P-analog, acting as non-selective potent agonist of S1PR1,3,4,5. The first S1PR modulator approved for the treatment of relapsing MS was fingolimod (Curtò et al., 2017; Peyrin-Biroulet et al., 2017a).

Various preclinical studies have demonstrated its efficacy at ameliorating colitis in animal models of IBD. Treatment of IL-10 knockout mice for 4 weeks efficiently reduced the number of CD4+ T cells in the colonic lamina propria and decreased the production of IFN-γ in the colon (Mizushima et al., 2004; Huwiler and Zangemeister-Wittke, 2018). Similar data were reported with other colitis models, such as dextran sulfate sodium (DSS), trinitrobenzene sulfonic acid, and T cell transfer into immunocompromised mice (Deguchi et al., 2006; Daniel et al., 2007; Radi et al., 2011; Montrose et al., 2013; Huwiler and Zangemeister-Wittke, 2018). The clinical use of fingolimod in IBD has not been tested, and other, more selective,
S1PR modulators are being developed for clinical use in IBD (Currò et al., 2017).

**KRP-203** (Novartis™) is a S1PR1,4,5 agonist and partial agonist of S1PR3. The safety, tolerance, and efficacy of KRP203 were tested in 27 patients with active moderate UC, in a multicenter, double-blind, placebo-controlled study (Radeke et al., 2016; Perez-Jeldres et al., 2018). KRP203 demonstrated adequate tolerance and safety. While KRP203 was shown to be minimally effective with regards to the clinically relevant threshold (novel Bayesian trial design), a 14% in the KRP203 group achieved clinical remission in comparison a 0% in the placebo group (Radeke et al., 2016; Perez-Jeldres et al., 2018). Based on the results of this small study, further development of KRP-203 for ulcerative colitis (UC) was terminated (ClinicalTrials.gov, ClinicalTrials, 2018a).

**Ozanimod/RPC1063** (Celgene™) is a S1PR agonist, with enhanced selectivity for S1PR1 and S1PR5 (Perez-Jeldres et al., 2018). Ozanimod is metabolized in humans to form one major active metabolite (CC-112273) and other minor active metabolites (RP101988 and RP101075). CC-112273 is responsible for much of the total activity of ozanimod in human with similar potency and selectivity to ozanimod to S1P1 and S1P5 (Scott et al., 2016). Ozanimod is eliminated primarily via biotransformation, followed by biliary excretion. Renal excretion is limited (Hemperly et al., 2018). Its half-life is 19 h, thus upon drug discontinuation, lymphocyte counts return to normal within 72 h (Scott et al., 2016; Hemperly et al., 2018; seekingalpha.com, 2018). However, new data show that the effect could be prolonged by the metabolite CC112273, which has a long 10–13 day half-life, reducing the competitive advantage of ozanimod on the key safety feature of the lymphocyte recovery profile (Scott et al., 2016; Hemperly et al., 2018; seekingalpha.com, 2018). Currently, there is an ongoing phase 1, randomized, parallel-group, open-label study to evaluate the effect of the modulators of the cytochrome P450 (CYP) 2C8 and/or 3A on the single-dose pharmacokinetics of ozanimod and CC112273 in healthy adult subjects (Scott et al., 2016; ClinicalTrials.gov, ClinicalTrials, 2018r; seekingalpha.com, 2018). The TOUCHSTONE phase 2 trial randomized 197 adults with moderate-to-severe UC to either ozanimod 0.5 or 1 mg or placebo daily for up to 32 weeks (Sandborn et al., 2016; White et al., 2018). After 8 weeks induction, 13.8 and 16.4% of patients (0.5 and 1 mg, respectively) reported clinical remission, versus 6.2% in the placebo group. At the same time, clinical response rates were achieved in 57, 54, and 37% for 1, 0.5, and placebo groups, respectively. Mucosal improvement/healing was observed in approximately 30% of the patients treated in each dose group in comparison with 12% in the placebo group. Moreover, at 32 weeks there was an observed improvement in the rates of clinical remission (21, 26, and 6% for 1, 0.5, and placebo, respectively), and 51% of the patients treated with 1 mg had a clinical response, versus 35 and 20% in the groups treated with 0.5 mg and placebo, respectively. Mucosal improvement/healing did not show major differences in comparison with 8 weeks. Ozanimod treatment (1 mg/kg dose) was associated with a greater proportion of histological remission (defined as a Geboes score ≤ 2) at both 8 and 32 weeks (Sandborn et al., 2016). The long-term follow-up of patients involved in TOUCHSTONE study demonstrated that ozanimod was safe, effective, and well tolerated (Sandborn et al., 2016; White et al., 2018).

Initial results of a phase 2, open-label study in 69 patients treated with ozanimod for moderate-to-severe CD demonstrated a meaningful clinical improvement at week 4 and endoscopic improvement at week 12 (Feagan et al., 2017). Phase 3 studies investigating the role of ozanimod in IBD are in progress (White et al., 2018).

**Etrasimod/APD334** (Arena™) is a S1PR1,4,5 selective agonist. Preliminary data from phase 2 OASIS trial in moderate-to-severe UC were reported (prnewswire.com, 2018). The primary objective, defined as an improvement in 3-component Mayo Clinic Score (stool frequency, rectal bleeding, and endoscopy), was met at 12 weeks. In addition, the 2 mg group achieved significant endoscopic improvement compared with placebo (41.8 versus 17.8%), and also the clinical remission was significant in the 2 mg group compared with placebo (24.5 versus 6.0%). Etrasimod was well tolerated and few patients had serious adverse events (SAEs). Arena plans to start a Phase 3 trial for UC (prnewswire.com, 2018).

**Amiselimod/MT-1303** (Mitsubishi Tanabe Pharma Corporation™) is an oral selective S1PR1,5 receptor developed for the therapy of autoimmune/immune-mediated disorders. The efficacy and safety of MT-1303 were studied in a phase 2 trial in CD, but the results have not yet been published (ClinicalTrials.gov, ClinicalTrials, 2018c,d). Amiselimod was also investigated for UC, MS, and other immune-mediated diseases; however, its development was discontinued (Feyrin-Biroulet et al., 2017a).

### Safety and Adverse Events

#### Infections

In general, S1PR modulators maintain immune surveillance against pathogens because their effects on effector memory T cell traffic are limited (Perez-Jeldres et al., 2018). However, serious infections, such as disseminated varicella zoster and herpes are rare, but have been reported with fingolimod (Pelletier and Hafler, 2012). In post-marketing surveillance studies, there have been cases of progressive multifocal leukoencephalopathy (PML) and cryptococcal meningitis with the treatment of fingolimod, and without previous use of natalizumab (Olivera et al., 2016; fda.gov, 2018). However, it is necessary to emphasize that the risk to develop PML is low with fingolimod in the absence of prior natalizumab treatment. It is estimated that the risk with fingolimod use is less 1:10,000 patients. The Novartis safety database has identified 15 cases of PML with the use of fingolimod in monotherapy, as of August 2017 (Berger et al., 2018).

#### Cardiovascular Events

Reported cardiovascular events include transient bradycardia, atrioventricular block, and hypertension with the fingolimod use (Olivera et al., 2016; Sandborn et al., 2016). These side effects are attributed to S1PR2 and S1PR3 modulation. The development of selective S1PR1 modulators could theoretically bypass these side effects. However, S1PR1
is found in atrial cardiomyocytes, leading to a dose-dependent reduction in heart rate. In the TOUCHSTONE trial, a patient with preexisting bradycardia developed an asymptomatic, transient bradycardia, and first-degree AV block. The episode was self-limited without the need for treatment. These side effects could be minimized with a gradual dose titration regimen (Olivera et al., 2016; Sandborn et al., 2016).

Malignancy
Isolated cases of breast and skin cancer have been identified (Pelletier and Hafler, 2012). Squamous-cell carcinoma of the skin was reported in the TOUCHSTONE trial in one patient on 1 mg of ozanimod. This patient had also received mercaptopurine for more than 2 years (Sandborn et al., 2016).

Leukopenia
A dose-dependent and sustained decrease in lymphocyte count has been reported, consistent with the drug's MOA. However, it is reversible with drug discontinuation (Peyrin-Biroulet et al., 2017b).

Pregnancy
The teratogenicity risk of this group of drugs is unknown, so it is not recommended for use during pregnancy (Scott et al., 2016).

Others Adverse Events
Pulmonary disorders, elevated liver enzymes, and macular edema have been reported (Olivera et al., 2016).

Future Directions for the S1P Pathway
Ponesimod, Ceralifimod, Siponimod AUY954, SEW2871, AUY954, W061, CS-0777, and GSK2018682 are currently being investigated for use in other autoimmune/immune-mediated disorders (Park and Im, 2017). The pathways involved in the synthesis, degradation, and the mechanism of transport of these molecules represent an attractive new area of research (Perez-Jeldres et al., 2018).

Sphingosine Kinases
There are two isoforms of sphingosine kinase (SphK), SphK1 and SphK2. TNF induces SphK1 activation, leading to cyclooxygenase-2 (COX-2) expression and production of prostaglandin E2 (PGE2) that may contribute to mucosal inflammation (Pettus et al., 2003). Moreover, SphK1 expression was found to be elevated in both colonic epithelial cells and inflammatory cells in patients with UC patients correlating with COX2 overexpression (Snider et al., 2009). Data from mice indicate that the SphK1/SIP pathway participates in the development and maintenance of intestinal inflammation (Snider et al., 2009; Wollny et al., 2017). Thus, inhibition of this enzyme could represent a potential new target.

Sphingosine Phosphatase
This enzyme, expressed in the gastrointestinal tract, catalyzes dephosphorylation of S1P to sphingosine, resulting in regulation of S1P levels. Elevated sphingosine phosphatase expression has been demonstrated in colitis and contributes to its pathogenesis by disrupting barrier integrity, indicating that its inhibition may have beneficial effects in IBD (Huang et al., 2016).

S1P Lyase
Sphingosine-1-phosphate lyase degrades S1P irreversibly. This enzyme is abundant in tissues (Wollny et al., 2017), maintaining low levels S1P in the colonic mucosa in relation with the blood. This favors lymphocyte recirculation from the intestine back into circulation. Its inhibition may impair intestinal lymphocyte egress, but its effect still remains unclear with evidence that shows amelioration of DSS colitis, while other studies show worsening disease (Degagné et al., 2014; Shirakabe et al., 2018).

Spinster Homolog 2
The expression of this intra- and extracellular S1P transporter is upregulated in patients with IBD. Thus, it may represent another way to regulate S1P levels for therapeutic purposes (Miklossy et al., 2013).

Positioning of Small Molecules in the Therapeutic Algorithm of IBD
The choice of IBD treatment must be personalized according to the activity, severity, phenotype, preferences of the patients, comorbidities, history of the therapies used previously, and surgery (Kornbluth and Sachar, 2010; Panes and Alfaro, 2017; Lichtenstein et al., 2018).

The current treatment for IBD is based on aminosalicylates, steroids, immunosuppressants, and biologic therapies (Kornbluth and Sachar, 2010; Panes and Alfaro, 2017; Lichtenstein et al., 2018). The 5-ASA compounds are used as first line in mild-to-moderate UC, and in some cases of IBD-associated arthritis (sulfasalazine). These drugs have an excellent safety profile. Immunosuppressants can be added during maintenance therapy in cases of moderate severity, or in combination with biologic therapy in moderate-to-severe cases due to their synergism or to decrease the immunogenicity of the biologic (Kornbluth and Sachar, 2010; Panes and Alfaro, 2017; Lichtenstein et al., 2018). In recent years, measuring drug and antibody levels has allowed optimization of biological therapies and assisted in avoiding misuse of biologics by under dosing or drug failure (absence of response despite adequate drug level) (Kornbluth and Sachar, 2010; Panes and Alfaro, 2017; Lichtenstein et al., 2018). The calcineurin inhibitors have a limited role in the treatment due their narrow therapeutic window and side effects. Thus, they are mostly being used as a bridge to another maintenance drug in cases of acute severe colitis refractory to corticosteroid. However, in this last case infliximab seems to be a better option, due to less toxicity in comparison with cyclosporine (Kornbluth and Sachar, 2010; Panes and Alfaro, 2017; Lichtenstein et al., 2018).
New SM offers an alternative to the current therapeutic arsenal, especially in cases of steroid-resistance and cases of nonresponse and/or are intolerance to conventional therapies. Precise positioning the new small drugs in the therapeutic armament for IBD is difficult in the absence of head-to-head randomized controlled trials. The SM have a role in the treatment of moderate-to-severe IBD due to the lack of immunogenicity, and potential intermittent “on-off” dosing without resultant antibody formation and loss of response.

Most information available is for tofacitinib, approved for UC moderate-to-severe active, being a good option in cases refractory to anti-TNFa. Its effectiveness in comparison with anti-TNF as first-line therapy in moderate-to-severe UC, their use as combination therapy for example with other drugs as vedolizumab, its sequential use with other drugs (for example, induction with tofacitinib, followed by vedolizumab), or even it uses in acute severe colitis refractory to steroids, must also be evaluated in clinical trials, before authoritative consensus recommendations. In the absence of head-to-head comparisons, the evidence favors the use of infiximab in hospitalized patients with acute severe colitis in perianal disease.

Furthermore, it is important to consider tofacitinib’s safety profile and may be premature recommend its use in combination with immunomodulators, anti-TNFa, and/or cyclosporine, until additional safety information is available.

Improved knowledge of the mechanisms regulating disease, by genome sequencing analysis, improved comprehension of the immunological pathways, and further understanding of the role of the microbiome, may lead to new targets. In fact, it is possible that future therapies will be chosen not only by considering traditional patient characteristics, but also based on the patient’s microbiome and immune genotype, as well as predictive modeling of drug responses validated prospectively.

CONCLUSION

Novel, orally available drugs represent a new and exciting option in the IBD therapeutic arsenal, showing efficacy and reasonable safety. However, more studies are required to define their safety related to infection, malignancy, and pregnancy. One of the clear advantages of SMs is their lack of immunogenicity and their short half-life which represents an advantage when adverse events may mandate interruption of therapy. Other advantages include the administration route, maintenance of T cell effector memory response, potentially lower manufacturing cost, and finally, the new agents are more receptor-specific (Perez-Jeldres et al., 2018). The positioning of these new drugs with relation to existing treatment paradigm remains uncertain.

AUTHOR CONTRIBUTIONS

JR-N, TP-J, WS conception of work. JR-N, TP-J design of work. JR-N, TP-J drafting of manuscript. JR-N, WS, DP, ÅY, DG, JB, TK, CT, SY, and LL critical revision of manuscript. JR-N, TP-J, WS, DP, ÅY, JB, TK, CT, DG, SY, and LL final approval of work. JR-N, TP-J, WS, DP, ÅY, JB, TK, CT, DG, LL, and SY agreement to be accountable for all aspects of presented work.

FUNDING

This work was funded by grants from the National Institutes of Health (DK108670) and VA Merit grant (BLRD-101 BX003436).
ClinicalTrials.gov (2018c). NCT02378688. Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Crohn's Disease. Available at: https://clinicaltrials.gov/ct2/show/NCT02378688?term=MT-1303&cond=Inflammatory+Bowel+Disease&rank=4 [accessed August 20, 2018].

ClinicalTrials.gov (2018d). NCT02389790. Extension Study of MT-1303 in Subjects With Crohn's Disease. Available at: https://clinicaltrials.gov/ct2/show/NCT02389790?term=MT-1303&cond=Inflammatory+Bowel+Disease&rank=4 [accessed August 20, 2018].

ClinicalTrials.gov (2018e). NCT02535689. Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus. Available at: https://clinicaltrials.gov/ct2/show/NCT02535689 [accessed August 12, 2018].

ClinicalTrials.gov (2018f). NCT02818686. TD-1473 for Active Ulcerative Colitis (UC). Available at: https://clinicaltrials.gov/ct2/show/NCT02818686 [accessed August 26, 2018].

ClinicalTrials.gov (2018g). NCT02819635. A Study to Evaluate the Safety and Efficacy of Upadacitinib (ART-494) for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis (UC). Available at: https://clinicaltrials.gov/ct2/show/NCT02819635?term=upaDACITINIBandcond=Inflammatory+Bowel+Disease&rank=6 [accessed August 26, 2018].

ClinicalTrials.gov (2018h). NCT02914522. Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis (SELECTION1). Available at: https://clinicaltrials.gov/ct2/show/NCT02914522?term=filgotinibandcond=Inflammatory+Bowel+Disease&rank=8 [accessed August 26, 2018].

ClinicalTrials.gov (2018i). NCT02914535. Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis (SELECTION2). Available at: https://clinicaltrials.gov/ct2/show/NCT02914535?term=filgotinibandcond=Inflammatory+Bowel+Disease&rank=7 [accessed August 26, 2018].

ClinicalTrials.gov (2018j). NCT02914600. Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease (DIVERSITY1). Available at: https://clinicaltrials.gov/ct2/show/NCT02914600 [accessed August 26, 2018].

ClinicalTrials.gov (2018k). NCT02958865. Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects with Moderate to Severe Ulcerative Colitis. Available at: https://clinicaltrials.gov/ct2/show/NCT02958865 [accessed August 26, 2018].

ClinicalTrials.gov (2018l). NCT03006068. A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ART-494) in Subjects with Ulcerative Colitis (UC). Available at: https://clinicaltrials.gov/ct2/show/NCT03006068?term=upaDACITINIBandcond=Inflammatory+Bowel+Disease&rank=5 [accessed August 26, 2018].

ClinicalTrials.gov (2018m). NCT03046056. Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SCBD). Available at: https://clinicaltrials.gov/ct2/show/NCT03046056?term=filgotinibandcond=Inflammatory+Bowel+Disease&rank=1 [accessed August 26, 2018].

ClinicalTrials.gov (2018n). NCT03100942. Safety and Efficacy Study of Filgotinib, GS-9876 and Tirabrutinib in Adults With Active Sjogren's Syndrome Syndrome. Available at: https://clinicaltrials.gov/ct2/show/NCT03100942 [accessed August 25, 2018].

ClinicalTrials.gov (2018o). NCT03345836. A Study of the Efficacy and Safety of Upadacitinib (ART-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy. Available at: https://clinicaltrials.gov/ct2/show/NCT03345836?term=upaDACITINIBandcond=Inflammatory+Bowel+Disease&rank=1 [accessed August 26, 2018].

ClinicalTrials.gov (2018p). NCT03345849. A Study of the Efficacy and Safety of Upadacitinib (ART-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional Therapies But Have. Available at: https://clinicaltrials.gov/ct2/show/NCT03345849?term=upaDACITINIBandcond=Inflammatory+Bowel+Disease&rank=4 [accessed August 26, 2018].

ClinicalTrials.gov (2018q). NCT03395184. Study to Evaluate the Efficacy and Safety of Oral PF-06651600 And PF-06700841 In Subjects With Moderate to Severe Crohn's Disease. Available at: https://clinicaltrials.gov/ct2/show/NCT03395184?term=PF-06700841andcond=Inflammatory+Bowel+Disease&rank=1 [accessed August 26, 2018].

ClinicalTrials.gov (2018r). NCT03624959. Drug-drug Interaction Study of Ozanimod With Inhibitor or Inducer of CYP2C8 and/or CYP3A. Available at: https://seekingalpha.com/article/4173916-2-cent-ozanimod-saga.html
New treatment strategies for ulcerative colitis.

Panes, J., and Alfaro, I. (2017). Tofacitinib for induction and maintenance therapy of Crohn’s disease: results of two phase IIb randomised placebo-controlled trials. Gut 66, 1049–1059. doi: 10.1136/gutjnl-2016-312733

Park, S. J., and Im, D. S. (2017). Sphingosine 1-phosphate receptor modulators and drug discovery. Biomol. Ther. 25, 80–90. doi: 10.4062/biomolther.2016.160

Pelleter, D., and Hafer, D. A. (2012). Fingolimod for multiple sclerosis. 2012. N. Engl. J. Med. 366, 339–347. doi: 10.1056/NEJMct1101691

Perez-Jeldres, T., Tyler, C. J., Boyer, D. J., Karuppuchamy, T., Bamias, G., Dulai, P. S., et al. (2018). Cell trafficking interference in inflammatory bowel disease: therapeutic interventions based on pathogenesis concepts. Inflamm. Bowel Dis. doi: 10.1093/ibd/izy269 [Epub ahead of print].

Pettus, B. J., Bielawski, J., Porcelli, A. M., Reames, D. L., Johnson, K. R., Morrow, J., et al. (2003). The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-alpha. FASEB J. 17, 1411–1421. doi: 10.1096/fj.02-1083com

Peyrin-Biroulet, L., Christopher, R., Behan, D., and Lassen, C. (2017a). Modulation of sphingosine-1-phosphate in inflammatory bowel disease. Autoimmun. Rev. 16, 495–503. doi: 10.1016/autrev.2017.03.007

Peyrin-Biroulet, L., Christopher, R., Trokan, L., Lassen, C., Adams, J., and Kühbacher, T. (2017b). Safety, Tolerability and Lymphocyte-Lowering Properties of Etrasimod (APD334), an Oral, Potent, Next-Generation, Selective S1P Receptor Modulator, After Dose Escalation in Healthy Volunteer. Available at: http://www.arenapharm.com/wp-content/uploads/2017/05/ECCO-Poster-Safety-and-Lymphocyte-Lowering-Final.pdf [accessed August 26, 2018].

prnewswire.com (2018). Arena Pharmaceuticals Reports Positive Phase II Results From the OASIS Trial for Etratym in Patients With Ulcerative Colitis. Available at: https://www.prnewswire.com/news-releases/arena-pharmaceuticals-reports-positive-phase-2-results-from-the-oasis-trial-for-etratym-in-patients-with-ulcerative-colitis-300616131.html [accessed August 20, 2018].

Radeke, H. H., Stein, J., and Krues, W. (2016). P372. A multicentre, double-blind, placebo-controlled, parallel group, proof of concept study to evaluate the efficacy, safety and tolerability of the S1P receptor modulator KRP203 in subjects with moderately active refractory ulcerative colitis. J. Crohn’s Colitis 10, S285–S286.

Razi, Z. A., Heuvelman, D. M., Masferrer, J. L., and Benson, E. L. (2011). Pharmacologic evaluation of sulfasalazine, FTY720, and anti-IL-12/23p40 in a TNBS-induced Crohn’s disease model. Dig. Dis. Sci. 56, 2283–2291. doi: 10.1007/s10620-011-1628-8

Samaden, J. (2013). “Similarities and differences in the discovery and use of biopharmaceuticals and small-molecule chemotherapeutics,” in Introduction to Biological and Small Molecule Drug Research and Development: Theory and Case Studies, eds R. Ganellin, S. Roberts, and R. Jefferis (Waltham, MA: Elsevier).

Sandborn, W. J., Bhandari, R., Leighton, J., Ganesahappa, R., Nguyen, D., Ferslew, B., et al. (2018a). The Intestinally Restricted, Orally Administered, Pan-Jak Inhibitor TD-1473 Demonstrate Favorable Safety, Tolerability, Pharmacokinetics, and Signal for Clinical Activity in Subjects With Moderately-to-Severely Active Ulcerative Colitis. Available at: https://www.ueg.eu/education/document/the-intestinally-restricted-orally-administered-pan-jak-inhibitor-td-1473-demonstrates-favorable-safety-tolerability-pharmacokinetics-and-signal-for-clinical-activity-in-subjects-with-moderately-to-severely-active-ulcerative-colitis/180035/ [accessed November 8, 2018].

Sandborn, W. J., Feagan, B. G., Panes, J., D’Haens, G. R., Colombel, J. F., Zhou, Q., et al. (2017b). Safety and efficacy of ABT-494 (Upadacitinib), an oral jak1 inhibitor, as induction therapy in patients with crohn’s disease: results from Celest. Gastroenterology 152, S1308–S1309. doi: 10.1056/S0016-5085(17)34357-3

Sandborn, W. J., Feagan, B. G., Wolf, D. C., D’Haens, G., Vermeire, S., Hanauer, S. B., et al. (2016). Ozanimod induction and maintenance treatment for ulcerative colitis. N. Engl. J. Med. 374, 1754–1762. doi: 10.1056/NEJMoa1513248

Sandborn, W. J., Ghosh, S., Panes, I., Schreiber, S., D’Haens, G., et al. (2018b). Efficacy and Safety of Upadacitinib as an Induction Therapy For Patients With Moderately-to-Severely Active Ulcerative Colitis: Data From the Phase 2B
Study U-Achieve. Available at: https://www.ueg.eu/education/document/efficacy-and-safety-of-upadacitinib-as-an-induction-therapy-for-patients-with-moderately-to-severely-active-ulcerative-colitis-data-from-the-phase-2b-study-u-achieve/180240 [accessed November 8, 2018].

Sandborn, W. J., Ghosh, S., Panes, J., Vranic, L., Wang, W., and Nieyzchowsk, W. (2014). A phase 2 study of Tofacitinib, an oral janus kinase inhibitor, inpatients with crohn’s disease. Clin. Gastroenterol. Hepatol. 12, 1485.e2–1493.e2. doi: 10.1016/j.cgh.2014.01.029

Sandborn, W. J., Su, C., Sands, B. E., D’Haens, G. R., Vermeire, S., Schreiber, S., et al. (2017a). Tofacitinib as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 376, 1723–1736. doi: 10.1056/NEJMoa1606910

Sandborn, W. J., Subatra, G., Panes, J., Vranic, L., Su, C., Roussel, S., et al. (2012). Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. New Engl. J. Med. 367, 616–624. doi: 10.1056/NEJMoa111268

Sands, B. E., Sandborn, W. J., Feagan, B. G., Lichtenstein, G. R., Zhang, H., Strauss, R., et al. (2018). Peficitin, an oral Janus kinase inhibitor, in moderate-to-severe ulcerative colitis: results from a randomized, phase 2 study. J. Crohns Colitis doi: 10.1093/ezcc-jcc/jjy085 [Epub ahead of print].

Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., and O’Shea, J. J. (2016). Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity. Br. J. Pharmacol. 173, 1779–1792. doi: 10.1111/bph.13476

Scott, F. L., Clemons, B., Brooks, J., Brahmachary, E., Powell, R., Dedman, H., et al. (2009). A role for sphingosine kinase 1 in dextran sulfate sodium-induced colitis. Am. J. Pathol. 173, 143–152. doi: 10.1096/faj.08-118109

Shirakabe, K., Higashiyama, M., Furuhashi, H., Takajo, T., Maruta, K., Okada, Y., et al. (2018). Amelioration of colitis through blocking lymphocytes entry to Peyer’s patches by sphingosine-1-phosphate lyase inhibitor. J. Gastroenterol. Hepatol. doi: 10.1111/1600-040X.Epub ahead of print.

Snider, A. J., Kawamori, T., Bradshaw, S. G., Ott, K. A., Gilkeson, G. S., Hannun, Y. A., et al. (2007). IL-23,1723–1736. doi: 10.1056/NEJMoa1606910

Soendergaard, C., Røgenheim, F. H., Bjerrum, J. T., and Nielsen, O. H. (2018). Targeting JAK-STAT signal transduction in IBD. Pharmacol. Ther. 192, 100–111. doi: 10.1016/j.pharmthera.2018.07.003

Vanhoutte, F., Mazar, M., Voloshyn, O., Stanislavchuk, M., Van der Aa, A., Namour, F., et al. (2017). Efficacy, safety, pharmacokinetics, and pharmacodynamics of filgotinib, a selective Janus kinase 1 inhibitor, after short-term treatment of rheumatoid arthritis: results of two randomized Phase IIa trials. Arthritis Rheumatol. 69, 1949–1959. doi: 10.1002/art.40186

Verden, A., Dimbil, M., Kyle, R., Overtreest, B., and Hoffman, K. B. (2018). Analysis of spontaneous postmarket case reports submitted to the FDA regarding thromboembolic adverse events and JAK inhibitors. Drug Saf. 41, 357–361. doi: 10.1007/s40264-017-0622-2

Vermeire, S., Schreiber, S., Petryka, R., Kuehbacher, T., Hebuterne, X., Robin, X., et al. (2017a). Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet 388, 266–275. doi: 10.1016/S0140-6736(16)32537-5

Vermeire, S., Van Der Aa, A., Jamoul, C., Tasset, P., Harrison, G., and D’Haens, R. (2017b). Effect of disease duration and location on clinical remission in Crohn’s disease patients treated with Filgotinib, a selective JAK1 inhibitor: post-hoc analysis from the phase 2 FITZROY study. United Eur. Gastroenterol. J. 5, A1–A160.

Villarino, A. V., Kanno, Y., Ferdinand, J. R., and O’Shea, J. J. (2015). Mechanisms of Jak/STAT signaling in immunity and disease. J. Immunol. 194, 21–27. doi: 10.4049/jimmunol.1400146

Villarino, A. V., Kanno, Y., and O’Shea, J. J. (2017). Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat. Immunol. 18, 374–384. doi: 10.1038/ni.3691

White, J. R., Phillips, F., Monaghan, T., Fateen, W., Samuel, S., Ghosh, S., et al. (2018). Review article: novel oral-targeted therapies in inflammatory bowel disease. Aliment. Pharmacol. Ther. 47, 1610–1622. doi: 10.1111/apt.14669

Winthrop, K. L. (2017). The emerging safety profile of Jak inhibitors in rheumatic diseases. Nat. Rev. Rheumatol. 13, 234–243. doi: 10.1038/nrrheum.2017.23

Wollny, T., Wątek, M., Durnai, B., Niemirowickz, K., Piekło, E., Żmudzian-Piotrowska, M., et al. (2017). Sphingosine-1-phosphate metabolism and its role in the development of inflammatory bowel disease. Int. J. Mol. Sci. 18:741. doi: 10.3390/ijms1804074

Yarur, A. J., and Rubin, D. T. (2015). Therapeutic drug monitoring of anti-tumor necrosis factor agents in patients with inflammatory bowel diseases. Inflamm. Bowel Dis. 21, 1709–1718. doi: 10.1097/MIB.0000000000003380

Zhang, H., Watanabe, R., Berry, G. J., Tian, L., Goronzy, J. J., and Weyand, C. M. (2018). Inhibition of Jak-STAT signaling suppresses pathogenic immune responses in medium and large vessel vasculitits. Circulation 137, 1934–1948. doi: 10.1161/CIRCULATIONAHA.117.030423

Zhou, L., Ivanov, I. I., Spolski, R., Min, R., Shenderov, K., Egawa, T., et al. (2007). IL-6 programs Th17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 8, 967–974. doi: 10.1038/ni1488

Conflict of Interest Statement: WS reports research grants from Atlantic Healthcare Limited, Amgen, Genentech, Gilead Sciences, Abbvie, Janssen, Takeda, Lilly, Celgene/Receptors; consulting fees from Abbvie, Allergan, Amgen, Boehringer Ingelheim, Celgene, Conatus, Cosmo, Escalier Biosciences, Ferring, Genentech, Gilead, Gossamer Bio, Janssen, Lilly, Miraca Life Sciences, Nivalis Therapeutics, Novartis Nutrition Science Partners, Oppilan Pharma, Otsuka, Paul Hastings, Pfizer, Precision IBd, Progenity, Prometheus Laboratories, Ritter Pharmaceuticals, Robarts Clinical Trials (owned by Health Academic Research Trust or HART), Salix, Shire, Sereis Therapeutics, Sigmod Biotechnologies, Takeda, Tigenix, Tillotts Pharma, UCB Pharma, Vivelix; and stock options from Ritter Pharmaceuticals, Oppilan Pharma, Escalier Biosciences, Gossamer Bio, Precision IBd, Progenity. AJ-R is consultant and part of the speaker bureau for Prometheus Laboratories and employee of Prometheus Laboratories. DP has been a speaker bureau Abbvie.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Pérez-Jeldres, Tyler, Boyer, Karuppuchamy, Yarur, Giles, Yeasmin, Lundborg, Sandborn, Patel and Rivera-Nieves. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.